JY-008

N/A

Report date: 2026/03/19 20:00:18

Base Information

Drug NameJY-008

Drug Alias NameCD7-targeted CAR-T cells therapy (Institute Of Hematology & Blood Diseases Hospital)JY008JY-008

ClassificationCell and gene therapy > Cell therapy > Immune system cell therapy > Lymphocytes therapy > T-lymphocyte cell therapy > Chimeric antigen receptor T cell therapy

Mechanisms of ActionT lymphocyte replacementsT-cell antigen CD7 modulators

TargetsT-cell antigen CD7

Therapy Area/IndicationsLeukemia, Myeloid, AcutePrecursor T-Cell Lymphoblastic Leukemia-Lymphoma

Global Approved IndicationsN/A

Approved Indications in ChinaN/A

Original Approved Country/TerritoryN/A

Original Approved DateN/A

Country/TerritoryN/A

CombinationsNo

Global Highest StatusPhase 1 Clinical

Highest Status in ChinaN/A

Originator CompaniesInstitute Of Hematology & Blood Diseases Hospital

China Registration ClassN/A

Develop Information

Active CompaniesInstitute Of Hematology & Blood Diseases Hospital

Inactive CompaniesN/A

Active IndicationsLeukemia, Myeloid, AcutePrecursor T-Cell Lymphoblastic Leukemia-Lymphoma

Inactive IndicationsN/A

Other Information

ATC CodeN/A